RXRX NASDAQ
Recursion Pharmaceuticals, Inc.
1W: +2.3%
1M: -16.6%
3M: -9.1%
YTD: -25.9%
1Y: -31.6%
3Y: -39.4%
5Y: -85.3%
$3.01
-0.10 (-3.22%)
After Hours: $3.03 (+0.02, +0.66%)
Weekly Expected Move ±7.1%
$3
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$75M
+26.9% ▲
5Y CAGR: +85.4%
Gross Profit
-$46M
-440.2% ▼
Operating Income
-$648M
-35.3% ▼
Net Income
-$645M
-39.1% ▼
EPS (Diluted)
$-1.44
+14.8% ▲
EBITDA
-$559M
-31.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $10M | $40M | $44M | $59M | $75M |
| YoY Growth | +193.0% | +296.8% | +12.3% | +32.0% | +26.9% |
| Cost of Revenue | $0 | $48M | $43M | $45M | $121M |
| Gross Profit | $10M | -$9M | $1M | $14M | -$46M |
| Gross Margin | 100.0% | -21.7% | 2.9% | 23.1% | -62.0% |
| R&D Expenses | $135M | $156M | $241M | $314M | $425M |
| SG&A Expenses | $58M | $82M | $111M | $178M | $177M |
| Operating Expenses | $193M | $237M | $351M | $493M | $602M |
| Operating Income | -$183M | -$246M | -$350M | -$479M | -$648M |
| Operating Margin | -1827.8% | -619.3% | -797.8% | -814.1% | -867.9% |
| Interest Expense | $3M | $55K | $97K | $2M | $2M |
| Income Before Tax | -$186M | -$239M | -$332M | -$465M | -$645M |
| Tax Expense | $0 | $0 | -$4M | -$1M | -$136K |
| Net Income | -$186M | -$239M | -$328M | -$464M | -$645M |
| Net Margin | -1864.8% | -603.5% | -747.7% | -788.0% | -863.4% |
| EPS (Diluted) | $-1.05 | $-1.36 | $-1.58 | $-1.69 | $-1.44 |
| EBITDA | -$175M | -$228M | -$308M | -$427M | -$559M |
| Shares Outstanding | 170M | 176M | 208M | 274M | 447M |